Why Hims & Hers Health Stock Soared Tuesday
Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements.The day's gain was powered by the telehealth company's announcement of plans to sell the blockbuster weight loss drug Zepbound on its platform.Hims & Hers revealed Tuesday that it will begin offering branded versions of Eli Lilly's tirzepatide -- the active ingredient in weight loss drug Zepbound and diabetes medicine Mounjaro. The company will also offer biosimilar versions of Novo Nordisk's diabetes drug liraglutide. It joins competitors Teladoc and LifeMD in offering Zepbound. Continue reading
Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements.
The day's gain was powered by the telehealth company's announcement of plans to sell the blockbuster weight loss drug Zepbound on its platform.
Hims & Hers revealed Tuesday that it will begin offering branded versions of Eli Lilly's tirzepatide -- the active ingredient in weight loss drug Zepbound and diabetes medicine Mounjaro. The company will also offer biosimilar versions of Novo Nordisk's diabetes drug liraglutide. It joins competitors Teladoc and LifeMD in offering Zepbound.
